Pfizer halts development of hep C drug filibuvir

03/13/2013 | Pharmaceutical Business Review Online

Pfizer said it would stop developing its midstage hepatitis C drug filibuvir, or PF-00868554. Potential competitors included new hepatitis C therapies from Gilead Sciences and AbbVie. "We continue to prioritize our [research and development] capital allocation to drive the next wave of innovative medicines and vaccines that bring benefit to patients and value to health care systems around the world," Pfizer's Victoria Davis said.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX